Summary
A practical guide to designing longevity research protocols using NAD+ precursors, Epitalon, MOTS-c, SS-31, and related compounds — covering mitochondrial biology, telomere science, protocol structure, and the current state of human evidence.
The Hallmarks of Ageing as a Framework for Protocol Design
Longevity research using peptides is most coherent when organised around the biological mechanisms through which ageing occurs — what researchers call the "hallmarks of ageing."
The nine hallmarks identified in the landmark 2013 López-Otín framework (expanded to twelve in 2023) include:
- Genomic instability
- Telomere attrition — addressed by Epitalon
- Epigenetic alterations
- Loss of proteostasis
- Disabled macroautophagy
- Deregulated nutrient sensing
- Mitochondrial dysfunction — addressed by SS-31, MOTS-c, NAD+
- Cellular senescence
- Stem cell exhaustion
- Altered intercellular communication
- Chronic inflammation ("inflammageing")
- Dysbiosis
The most targeted longevity peptide protocols address hallmarks 2 and 7 — telomere attrition and mitochondrial dysfunction — because these are the mechanisms with the clearest peptide-based intervention points and the most developed evidence base.
NAD+: The Mitochondrial Fuel Molecule
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, functioning as the central electron carrier in cellular energy metabolism and as a substrate for sirtuin (SIRT1–7) deacetylases — enzymes that regulate gene expression, DNA repair, and mitochondrial biogenesis.
Why NAD+ Declines With Age
Human brain NAD+ levels measured by in vivo magnetic resonance spectroscopy (Zhu et al., 2015) decline by approximately 10% per decade from age 20 to 80. This decline is attributed to:
- Reduced biosynthesis via the salvage pathway (lower NAMPT enzyme activity)
- Increased consumption by PARPs (activated by age-related DNA damage)
- Increased consumption by CD38 (an NAD+ hydrolase whose expression rises with ageing)
The consequence is a progressive energy deficit in mitochondria and reduced sirtuin activity — both linked to accelerated cellular senescence.
NAD+ in Research Protocols
Injectable NAD+ achieves rapid plasma elevation that oral precursors cannot match in kinetics. Research protocols using injectable NAD+ are studied for:
- Neurological function: NAD+ is neuroprotective under oxidative and ischaemic conditions; depletion is associated with accelerated neurodegeneration
- Cardiovascular metabolism: Sirtuin activation by NAD+ regulates mitochondrial biogenesis in cardiac tissue
- Muscle energetics: Age-related muscle wasting (sarcopenia) has been linked to declining NAD+ in skeletal muscle
Course-based protocols (5–10 day IV or subcutaneous loading periods) are more common in research than continuous daily dosing, reflecting NAD+'s roles as both an acute energy substrate and a longer-acting epigenetic regulator.
Epitalon: Telomerase Activation and Telomere Biology
Epitalon (also written Epithalon or Epitalone) is a synthetic tetrapeptide — Ala-Glu-Asp-Gly — developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It has one of the most specific longevity mechanisms studied in peptide research: activation of telomerase.
The Telomere Clock
Telomeres are repetitive DNA sequences (TTAGGG repeats) that cap the ends of chromosomes and protect them from degradation. Each time a somatic cell divides, telomeres shorten slightly. When telomeres reach a critical minimum length, the cell enters senescence or apoptosis — the Hayflick limit. Telomere length is therefore one biological clock that measures cellular ageing.
Epitalon's Mechanism
Epitalon activates telomerase — the ribonucleoprotein enzyme that extends telomeres by adding TTAGGG repeats. In normal somatic cells, telomerase is not expressed (it is suppressed to prevent uncontrolled cell division). Epitalon appears to reactivate or upregulate telomerase expression in these cells without inducing the uncontrolled proliferation associated with cancer.
Published human data: A small controlled study by Khavinson et al. (2003) demonstrated measurable telomere elongation and increased telomerase activity in peripheral blood cells of elderly subjects following Epitalon administration. This is among the very few published human data points for any telomerase-activating compound.
Protocol Design for Epitalon Research
The clinical protocols used in published studies involved course-based administration — typically 10-day courses administered twice yearly (spring and autumn). This cyclical approach reflects the hypothesis that Epitalon triggers lasting epigenetic changes rather than requiring continuous receptor occupation, similar to the logic behind pulsed peptide approaches in other areas.
MOTS-c: The Mitochondrial Metabolic Signal
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — the first mitochondrial-derived peptide (MDP) discovered to have nuclear transcriptional regulatory effects. Its discovery in 2015 by Lee et al. at the University of Southern California represented a significant shift in understanding of mitochondria-to-nucleus communication.
Why MOTS-c is Studied for Ageing
- AMPK activation: MOTS-c activates AMP-activated protein kinase, the cellular energy sensor that drives mitochondrial biogenesis and fatty acid oxidation
- Folate cycle regulation: MOTS-c modulates one-carbon metabolism, which intersects with methylation and nucleotide biosynthesis — core to epigenetic regulation and DNA repair
- Age-related decline: Circulating MOTS-c levels in humans decline with age and are lower in metabolically dysfunctional populations
- Lifespan extension: MOTS-c administration extended lifespan in C. elegans models and improved metabolic markers in aged mice, including insulin sensitivity and physical capacity
MOTS-c is studied primarily in metabolic disease and ageing contexts. Its unique mitochondrial origin and retrograde signalling mechanism make it mechanistically distinct from all nuclear-genome-derived peptides.
SS-31: Cardiolipin Protection and Mitochondrial Integrity
SS-31 (Elamipretide) is a synthetic tetrapeptide developed by Hazel Szeto at Cornell/Weill. It selectively targets the inner mitochondrial membrane by binding to cardiolipin — an unusual phospholipid present almost exclusively in the inner mitochondrial membrane, where it is critical for cristae architecture and electron transport chain function.
What SS-31 Does
Cardiolipin integrity declines with age and oxidative stress, causing mitochondrial cristae to collapse and electron transport chain complexes to become misaligned — directly reducing ATP production efficiency. SS-31 stabilises cardiolipin, protects cristae structure, and maintains electron transport chain supercomplex assembly.
In aged animal models, SS-31 produces:
- Restored mitochondrial membrane potential
- Improved ATP production
- Reduced reactive oxygen species (ROS) generation
- Improved skeletal muscle function and exercise capacity
- Cardiac protection in ischaemia-reperfusion models
SS-31 is the most cardiovascular-focused compound in the longevity peptide space. Researchers studying cardiac ageing, heart failure, and cardiometabolic disease are the primary users of SS-31-based protocols.
Designing a Longevity Research Stack
Longevity protocols are typically organised around targeting multiple hallmarks simultaneously, since no single compound addresses all relevant mechanisms of ageing.
Single-Hallmark Protocols
| Objective | Primary Compound | Mechanism Addressed |
|---|---|---|
| Telomere biology | Epitalon | Telomerase activation |
| Mitochondrial bioenergetics | SS-31 | Cardiolipin / ETC integrity |
| Metabolic ageing | MOTS-c | AMPK / mitochondrial signalling |
| NAD+ restoration | Injectable NAD+ | Sirtuin activation / energy metabolism |
Multi-Hallmark Combinations
Core longevity stack (3 pathways):
- Epitalon — telomere biology
- NAD+ — sirtuin activation and mitochondrial bioenergetics
- MOTS-c — metabolic AMPK signalling
This combination addresses three independent longevity mechanisms with no mechanistic overlap, making it the most comprehensive single-stack approach available within a peptide-based framework.
Cardiovascular-focused longevity:
- SS-31 — mitochondrial membrane integrity
- NAD+ — sirtuin-driven cardiac protection
- Epitalon — cellular senescence reduction
Protocol Duration and Course Design
Longevity protocols differ fundamentally from acute-outcome protocols (fat loss, injury recovery) in their expected timelines. Ageing operates on years to decades; research endpoints must be matched to realistic measurement windows.
Epitalon: Published research uses 10-day courses twice yearly. This pulsed schedule reflects the compound's epigenetic mechanism — effects on gene expression and telomere biology persist beyond the dosing window.
NAD+: Injectable loading courses (3–10 days of concentrated dosing) are commonly used to elevate tissue NAD+ rapidly, followed by lower-frequency maintenance dosing. Oral precursor supplementation between courses may sustain elevated baseline levels.
MOTS-c: Preclinical studies have used continuous administration in aged mice. Human protocols are early-stage; course-based approaches are the convention pending more human data.
SS-31: Cardiovascular studies have used both acute (single-dose) and chronic (continuous daily) protocols depending on the endpoint — acute myocardial protection requires immediate presence; mitochondrial remodelling in aged muscle requires sustained administration.
Frequently Asked Questions
What is the most important longevity compound to start a research protocol with?
There is no universal answer — the starting point should match the specific research hypothesis. For researchers focused on cellular ageing mechanisms, Epitalon has the most specific evidence for its stated mechanism (telomerase activation) and a small but direct human data set. For researchers focused on metabolic ageing and physical capacity, NAD+ or MOTS-c are more directly relevant. For cardiovascular ageing research, SS-31 has the strongest mechanistic specificity.
How is longevity research measured when outcomes occur over decades?
Surrogate biomarkers are the practical solution for research protocols. Commonly studied surrogate endpoints include: telomere length (via qPCR or FISH), NAD+ tissue levels (via MRS or blood assays), mitochondrial function markers (VO2 max, lactate threshold), inflammatory markers (CRP, IL-6, TNF-α), epigenetic age clocks (Horvath methylation clock), and metabolic markers (insulin sensitivity, lipid profile, HbA1c).
Is there evidence that longevity peptides extend human lifespan?
No direct human lifespan extension data exists for any compound in this category — such data would require multi-decade controlled trials that have not been conducted. The evidence consists of preclinical lifespan extension (C. elegans, rodents), human biomarker improvements (telomere length, NAD+ levels, inflammatory markers), and mechanistic plausibility from molecular biology. The research hypothesis is that addressing these biomarkers will translate to improved healthspan — the period of healthy, functional life — even if direct lifespan effects cannot be confirmed in shorter human trials.
Source Research-Grade Longevity Compounds in Bali
BioPepTech lists Epitalon, NAD+, MOTS-c, and SS-31 for research use in Bali. Review product pages for current formats, available batch records, and delivery confirmation.
- Epitalon — Telomerase activator; the most specifically targeted telomere biology compound
- NAD+ — Injectable form for rapid tissue NAD+ elevation; sirtuin and mitochondrial support
- MOTS-c — Mitochondrial-derived metabolic peptide; AMPK activation and metabolic ageing
- SS-31 — Cardiolipin protector; mitochondrial membrane integrity and cardiac research
A free expert consultation is included with every order. Our research team can help design a longevity protocol matched to your specific research hypotheses and measurement framework.
References
Khavinson VK et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592.
Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
Zhu XH et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci USA. 2015;112(9):2876-2881.
López-Otín C et al. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278.
Research Use Only Disclaimer
BioPepTech products are supplied strictly for research use only. They are not intended for human consumption and are not intended to diagnose, treat, cure, or prevent disease.
Safety & Regulatory Note
Longevity compounds discussed are for research use only. Epitalon's evidence base comes predominantly from Russian research groups with limited independent replication. NAD+ administered intravenously at high concentrations has been associated with flushing and cardiovascular effects requiring rate-controlled infusion. MOTS-c and SS-31 are early-stage research compounds. All protocols should be supervised by a qualified medical professional.
References
- 1.Khavinson V et al. Peptide regulation of ageing. Russ J Genet. 2003;39(11):1334-1351.
- 2.Khavinson VK et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592.
- 3.Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- 4.Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
- 5.Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
- 6.Zhu XH et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci USA. 2015;112(9):2876-2881.